Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months
Until recently, ondansetron was approved for the prevention of nausea and vomiting only in patients older than 2 years. However, as the use of ondansetron in patients younger than 2 years had been documented, characterization of ondansetron pharmacokinetics in this younger pediatric age group was warranted.
The pharmacokinetics of intravenously administered ondansetron were evaluated in oncology and surgical patients aged 1–48 months. Pooled data from 124 patients, including 745 pharmacokinetic samples, were analyzed using nonlinear mixed-effects modeling.
Ondansetron pharmacokinetics were described by a two-compartment model. Body-size effects on ondansetron disposition were accounted for via standard allometric relationships, normalized to 10.4 kg. A maturation process with a half-life of approximately 4 months was incorporated to describe a decrease in clearance (CL) in infants. Clearance [95% confidence interval (CI)] for a typical patient was 1.53 (1.34−1.78) L/h/kg0.75 with an interindividual variability of 56.8%. Ondansetron CL was reduced by 31%, 53%, and 76% for the typical 6-month-, 3-month-, and 1-month-old patient, respectively. Simulations showed that an ondansetron dose of 0.1 mg/kg in children younger than 6 months produced exposure similar to a 0.15-mg/kg dose in older children.
The population pharmacokinetic analysis of ondansetron allows for characterization of individual patients based on body weight and age. It is recommended that patients younger than 4 months receiving ondansetron be closely monitored.
KeywordsOndansetron Population pharmacokinetics Pediatric
Brendan M. Johnson acknowledges support from a Clinical Pharmacokinetics/ Pharmacodynamics Fellowship provided by the University of North Carolina in collaboration with GlaxoSmithKline. The authors wish to acknowledge the following investigators of Study 1: Raafat Hannallah, Peter Davis, Joseph Tobin, and Victor Baum; and investigators who contributed pharmacokinetic data to Study 2: Jeanette Pullen, Lia Gore, Victor M. Aquino, Lisa Bomgaars, Jeffrey Blumer, Paul Gaynon, Stuart Goldman, Regina Jakacki, Mitchell Cairo, Henry Nicholson, Violet Shen, Burton Appel, James Alan Whitlock, Maxine L. Hetherington, Helen Irving, Amos Toren, Andreas Zoubek, Robert Klaassen, Purificacion Garcia-Miguel, and Arturo Munoz-Villa. The authors also wish to acknowledge Sharon C. Murray, Andrew P. Beelen, Linda M. Blackburn, Maura T. Watmuff, Vince Barnett, and Bonnie Whitehead of GlaxoSmithKline.
- 1.Bryson JC, Pritchard JF, Shurin S, Kernodle AE, Blumer JL (1991) Efficacy, pharmacokinetics (PK) and safety of ondansetron (OND) in pediatric chemotherapy patients (PTS). Clin Pharmacol Ther 49(2):161Google Scholar
- 7.Khalil SN, Roth AG, Cohen IT, Simhi E, Ansermino JM, Bolos ME, Coté CJ, Hannallah RS, Davis PJ, Brooks PB, Russo MW, Anschuetz GC, Blackburn LM (2005) A double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesia. Anesth Analg 101(2):356–361CrossRefPubMedGoogle Scholar
- 8.ZOFRAN Product Information (2005) GlaxoSmithKline, Research Triangle Park, NC Google Scholar
- 12.Hattis D, Ginsberg G, Sonawane B, Smolenski S, Russ A, Kozlak M, Goble R (2003) Differences in pharmacokinetics between children and adults–II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal 23(1):117–142CrossRefPubMedGoogle Scholar
- 23.Beal S, Sheiner BL (1992) NONMEM Users Guide. NONMEM Project Group, University of California at San FranciscoGoogle Scholar
- 25.Dubois D, Du Bois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863–871Google Scholar